Immune system
A germ-killing peptide discovered in frog skin — the find that launched the whole field of antimicrobial peptides; a derivative reached late-stage trials for diabetic foot ulcers.
Start here
Magainin-2 is a germ-killing peptide discovered in 1987 in the skin of the African clawed frog. It destroys bacteria and fungi by punching holes in their protective membranes — a mode of attack that bacteria have shown very little ability to develop resistance against. A synthetic derivative, pexiganan, reached Phase III human trials for infected diabetic foot ulcers, but magainin-2 itself is a research compound, not FDA-approved.
Magainin-2 is an antimicrobial peptide from frog skin that kills bacteria and fungi by disrupting their protective cell membranes, showing promise for treating wounds and infections.
Magainin-2 is a straight chain of 23 amino acids that fights germs. It was first found in the skin of the African clawed frog (Xenopus laevis). It folds into an α-helix (a spiral shape) and pushes into the fatty membranes of bacteria and fungi. This wipes out the membrane's electrical charge (depolarization), makes it leaky (permeabilization), and breaks down the electrical voltage across it. The cell's contents leak out and the bacterium dies. Its action depends little on the exact fats in a bacterial membrane, so it works on many Gram-positive and Gram-negative bacteria (two bacteria types, grouped by cell wall). Magainin-2 also calms inflammation by reducing TNF-α, IL-1, and IL-6 (inflammation signals) and promotes tissue regeneration (regrowth) by mimicking growth factors (signals that tell cells to grow).
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Fighting Infections
This peptide punches holes in bacteria and fungi within minutes, working against many types that other drugs can't touch.
Preventing Germ Resistance
Bacteria struggle to develop resistance to this peptide because it attacks their basic membrane structure rather than specific targets.
Wound Healing
Beyond killing germs, it helps skin cells grow and wounds close faster in animal studies. *Based on limited human evidence
The most-asked question
The research-reported range is 1 %, multiple times daily.
Mildly infected diabetic foot ulcers, Topical antimicrobial research
1% cream (pexiganan, a modified version of magainin-2)
Pexiganan (MSI-78), a synthetic magainin-2 analog (a modified version of a natural molecule), was tested as a 1% topical cream in Phase 3 diabetic foot-ulcer trials and matched oral ofloxacin for clinical improvement (~85-90%) 6. Native magainin-2 itself has no approved human dosing; figures reflect its clinical-stage analog.
The ceiling: 5 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Magainin-2:
Magainin-2 comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Magainin-2 exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Magainin-2's recorded schedule.
Timing
Apply Magainin-2 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
As a topical product, Magainin-2 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
Magainin-2 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild burning or stinging sensation at the topical application site, lasting 5-15 minutes after application. Reported in 5-10% of patients in Phase III trials.
What to do Self-limiting and resolves quickly. Cool compresses if needed. Does not require discontinuation of treatment.
Mild redness and warmth surrounding the application site, indicating local immune activation and vasodilation (widening blood vessels).
What to do Normal inflammatory response — often indicates active immune engagement with the infection. Monitor for progression. Resolves as treatment continues.
Itching at wound margins, more common during the healing phase as epithelial (surface-lining tissue) migration and nerve regeneration occur.
What to do Avoid scratching to prevent wound disruption. Cool compresses. Antihistamine cream at wound margins (not on wound bed) if needed.
Transient increase in wound drainage in the first 24-48 hours as bacteria are killed and cellular debris is released.
What to do Change dressings more frequently. Normal response to bacterial killing. Should decrease by day 3-4 of treatment.
Worth knowing about, but most people never see these.
Development of localized allergic contact dermatitis with prolonged or repeated exposure to magainin-based formulations.
What to do Discontinue treatment if persistent dermatitis develops. Patch testing may be useful. Switch to alternative antimicrobial if needed.
Rare, but if any of these happen, stop and contact a medical professional.
Phase III clinical trials with topical Pexiganan showed no serious systemic (affecting the whole body) adverse effects. 2 The topical route limits systemic absorption, and the peptide is rapidly degraded by tissue proteases if absorbed.
What to do As with any antimicrobial, discontinue and seek medical attention for unexpected severe local or systemic (affecting the whole body) reactions.
Week by week
Is it right for you?
Magainin-2 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Magainin-2. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Magainin-2 is particularly well-suited for individuals focused on research into topical antimicrobial peptides for diabetic foot ulcer management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Magainin-2 is particularly well-suited for individuals focused on understanding the toroidal pore model of antimicrobial peptide membrane disruption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Magainin-2 is particularly well-suited for individuals focused on development of resistance-proof antimicrobial agents targeting membrane architecture. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Magainin-2 is particularly well-suited for individuals focused on investigation of selective anticancer activity mediated by membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies 2 with minimal systemic (affecting the whole body) absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics.
Electron microscopy confirmed the germ-killing mechanism: it forms pores in the membranes of Gram-negative bacteria. 5 MIC values (the lowest concentration that stops growth) of 2-10 μM for Pseudomonas aeruginosa and Staphylococcus aureus were documented using broth microdilution assays (lab tests that grow bacteria in diluted drug). Wound healing studies using histopathology (microscope examination of tissue) show faster re-epithelialization (new skin growing over the wound) with faster collagen deposition. Skin safety testing confirms non-irritant status per OECD 404 at concentrations up to 2%.
Keeping it good
Store Magainin-2 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Magainin-2 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
1999
A magainin-like peptide called pexiganan kills a wide range of Gram-positive and Gram-negative bacteria (two bacteria types, grouped by cell wall) from diabetic foot ulcers (open sores on the feet), without cross-resistance to other antibiotics (resistance to it does not carry over to other antibiotics).
Ge Y, MacDonald D, Henry MM, et al.
2008
Research (2008) shows magainin 2 is a strong germ killer that works against a wide range of disease-causing microbes.
Lipsky BA, Holroyd KJ, Zasloff M
2020
Study (1996) explains, at the molecular level, how magainin 2 works and which pathways in the body produce its therapeutic effects.
McMillan KAM, Coombs MRP
2022
Research (2006) shows magainin 2 is a strong germ killer that works against a wide range of disease-causing microbes.
Hossain F, Billah MM, Yamazaki M
2025
Study (2006) describes what magainin 2 does in living systems and how it works.
Sancho-Vaello E, Kücükyildiz H, Gil-Carton D, et al.
2008
Phase 3 randomized controlled trials of 1% topical pexiganan (a magainin-2 analog, meaning a close copy) twice daily showed clinical improvement equal to oral ofloxacin (an antibiotic taken by mouth) (~85-90%), with no emergent pexiganan resistance (no resistance to pexiganan appeared).
Lipsky BA, et al. (Clinical Infectious Diseases)
If this isn't the right fit
Your questions
In 1999, the FDA advisory committee voted against Pexiganan (MSI-78) approval despite an 835-patient Phase III trial showing clinical cure rates comparable to oral ofloxacin for mildly infected diabetic foot ulcers. The primary concern was that Pexiganan was not demonstrated to be superior to existing treatments — the trial showed non-inferiority but the FDA panel wanted evidence of a distinct clinical advantage. Additionally, there were questions about whether a topical agent could adequately treat infections that might benefit from systemic (affecting the whole body) therapy. A second Phase III trial was initiated by Dipexium Pharmaceuticals in 2014 but did not achieve its primary endpoint.
In 1987, Dr. Michael Zasloff, a physician-scientist at the National Institutes of Health, noticed that African clawed frogs (Xenopus laevis) recovered from surgical procedures without developing wound infections despite being returned to non-sterile aquarium water teeming with bacteria. This observation led him to investigate the frogs' skin secretions, where he isolated magainin-1 and magainin-2 — potent antimicrobial peptides that provided the frogs with a chemical shield against infection. The discovery launched an entirely new field of antimicrobial peptide research.
The toroidal pore model describes how magainin-2 disrupts bacterial membranes. When enough magainin-2 molecules accumulate on the membrane surface (reaching a critical peptide-to-lipid ratio), they insert into the bilayer and induce the lipid head groups to curve inward, forming barrel-shaped pores lined by both peptide molecules and lipid head groups — hence 'toroidal' or 'wormhole' shape. These pores are approximately 2-3 nm in diameter and allow uncontrolled ion leakage, dissipation of transmembrane potential, and rapid bacterial death. This is distinct from the barrel-stave model where pores are lined exclusively by peptide.
Resistance is exceptionally hard to develop because magainin-2 targets the basic physical structure of bacterial membranes rather than a specific protein or enzyme. To resist magainin, bacteria would need to completely restructure their membrane fats, replacing anionic phospholipids (negatively charged membrane fats) with neutral ones. That would damage membrane function that bacteria need to survive. Serial passage experiments (repeated re-exposure over many generations) that exposed bacteria to sub-inhibitory magainin concentrations for over 1,200 generations (equivalent to decades of clinical use) showed no significant resistance development.
Yes, magainin-2 shows selective anticancer activity because cancer cells, unlike normal mammalian cells, expose anionic phosphatidylserine (PS) on their outer membrane leaflet. Normal cells maintain PS on the inner leaflet, making their outer surface neutral and resistant to magainin binding. Cancer cells with exposed PS are targeted similarly to bacteria. Studies have shown cytotoxicity against bladder carcinoma, melanoma, and hematopoietic tumor cell lines at concentrations of 40-150 µg/mL, though this is higher than bactericidal concentrations.
Pexiganan (MSI-78) is a synthetic 22-amino-acid derivative of magainin-2 designed for enhanced antimicrobial potency. Key differences: Pexiganan has an amidated C-terminus for increased stability and a higher net positive charge through strategic lysine substitutions. These modifications improve membrane binding affinity and reduce the minimum inhibitory concentration from 80-160 µg/mL (magainin-2) to 1.25-40 µg/mL (Pexiganan) against clinical isolates — a 4-100 fold improvement in potency. Pexiganan retains the toroidal pore mechanism and low resistance potential of the parent compound.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Magainin-2 research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Magainin-2 is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek